Received Mar 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | Unknown | PO / MO |
The patient had eaten before taking the first dose of Vivotif; Case reference number US-BN-2024-002816 is a spontaneous case initially received from a nurse via Med Communications (reference number: USBAV24-3125) on 26-Nov-2024 and concerns a 34-year-old male patient. The patient had no medical history. The patient's concomitant medications were not provided. On 26-Nov-2024, the patient took the first dose of Vivotif vaccine (batch number: unknown; expiration date: unknown) at a dose of one capsule, orally, for indication reported as pre travel. As reported, the patient had eaten before taking first dose of Vivotif (explicitly coded as 'product administration error'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20241126-c9b4ff to US-BAVARIAN NORDIC A/S-US-BN-2024-002816, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A 34-year-old male patient took the first dose of Vivotif vaccine for indication reported as pre travel. As reported, the patient had eaten before taking the first dose of Vivotif, which is considered as product administration error. It was unknown if the patient experienced any adverse event due to Vivotif. Product administration error is considered as listed per company convention. The patient had no medical history, and concomitant medications were not provided. Product administration error is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 34-year-old male patient took the first dose of Vivotif vaccine for indication reported as pre travel. As reported, the patient had eaten before taking the first dose of Vivotif, which is considered as product administration error. It was unknown if the patient experienced any adverse event due to Vivotif. Product administration error is considered as listed per company convention. The patient had no medical history, and concomitant medications were not provided. Product administration error is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None